chrisvoncsefalvay/vaers-outcomes huggingface dataset:
they must have hit a nerve or something because she immediately developed numbness and tingling in her fingers for several hours; they must have hit a nerve or something because she immediately developed numbness and tingling in her fingers for several hours; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 48 year-old female patient received bnt162b2 (BNT162B2), administered in arm right, administration date 29Apr2021 (Lot number: EW0179) at the age of 47 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Overweight" (unspecified if ongoing), notes: She states she is definitely overweight. There were no concomitant medications. Vaccination history included: Bnt162b2 (DOSE 1, Vaccine Name: First dose , Lot Number / Expiry Date: EW0162/ Unknown, Route, Anatomical Location:  Left arm , No. of Previous Doses: This was dose 1, Date: 07Apr2021), administration date: 07Apr2021, when the patient was 47 years old, for COVID-19 immunization.  The following information was reported: PARAESTHESIA (non-serious), HYPOAESTHESIA (non-serious) all with onset 29Apr2021, outcome "recovered" and all described as "they must have hit a nerve or something because she immediately developed numbness and tingling in her fingers for several hours". The event "they must have hit a nerve or something because she immediately developed numbness and tingling in her fingers for several hours" and "they must have hit a nerve or something because she immediately developed numbness and tingling in her fingers for several hours" was evaluated at the emergency room visit.  No follow-up attempts are possible. No further information is expected.
Evening of vaccination: Itchy throat and skin. Treated w OTC antihistamine  Next day; Flu-like symptoms: aching joints, weakness, low grade fever New this vaccine: nausea, lightheaded ness, fainting All symptoms gone on third day
1st day- sore left arm, itching in left arm and slight itching on left side of body 2nd day- malaise, lethargy, pain in left arm, headache on left side 3rd day- some  malaise, pain in left arm, headache 4th  day- swelling in front of left arm pit (lymphadenopathy) minor pain in left arm
Information has been received from a physician concerning a 5 year old female who on 26-APR-2007 was vaccinated with measles virus vaccine live (Enders-Edmonston) (+) mumps virus vaccine live (Jeryl Lynn) (+) rubella virus vaccine live (Wistar RA 27/3). There were no concomitant medications. Seven days after receiving the measles virus vaccine live (Enders-Edmonston) (+) mumps virus vaccine live (Jeryl Lynn) (+) rubella virus vaccine live (Wistar RA 27/3), on 03-MAY-2007, the patient developed a generalized "measles like" rash (number of lesions unspecified). No other information was available at the time of this report. Unspecified medical attention was sought. No product quality complaint was involved. Additional information has been requested.
pharmacy administered Trumenba instead of Bexsero; This non-serious case was reported by a physician via call center representative and described the occurrence of interchange of vaccine products in a male patient who received Men B NVS (Bexsero) for prophylaxis.   Co-suspect products included MENINGOCOCCAL B VACCINE (TRUMENBA) for prophylaxis.   On 02-JUN-2023, the patient received the 1st dose of Bexsero. On 05-JUL-2023, the patient received TRUMENBA. On an unknown date, an unknown time after receiving Bexsero, the patient experienced interchange of vaccine products (Verbatim: pharmacy administered Trumenba instead of Bexsero). The outcome of the interchange of vaccine products was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK receipt date: 6-Jul-2023 The case was reported by Dentist. The reporter gave permission for follow-up. The patient received first dose of Bexsero and went back to the pharmacy for the second dose, but the pharmacy administered Trumenba instead of Bexsero, which led to interchange of vaccine products.
Systemic: Seizure-Mild, Additional Details: PER PATIENT, LAST SEIZURE EVENT WAS 4 OR 5 YEARS AGO. THE PATIENT DID NOT VOMITTING DURING EVENT. PATIENT COLLAPSED, FACE FORWARD, THEN SHE MOVED ON TO HER SIDE AND STARTED SHAKING. EMS CAME AND TOOK HER VITALS AND ASKED HER QUESTIONS. PATIENT WAS ABLE TO WALK AFTERWARDS AND DECLINED ANY ADDITIONAL TREATMENTS FROM THE EMS. PATIENT WILL FOLLOW UP WITH HER DOCTOR.
Baby screamed and cried in a panicked manner and was inconsolable even with breastfeeding for at least 9-10 hours.  She had difficulty sleeping that night and was not her normal self until the following morning.  I called the doctor and spoke with the advice nurse and was told that this was a normal reaction, however if I would have known more I would have taken my baby to the emergency room and I remain concerned about what happened.
A report was received from a health care professional on 10/27/2003 concerning a 36 year old female vaccinee who inadvertently received expired Fluvirin vaccine on 10/27/2003. On 10/27/03, the vaccinee was inadvertently administered Fluvirin vaccine for the 2002-2003 flu season.  The vaccinee received 0.5 ml fluvirin intramuscularly in her deltoid. No adverse events were reported. There was insufficient information to determine the reporter's causality assessment. Update report, 1/13/04: Follow up information received from a health care professional indicated the Fluvirin vaccine administered on 10/27/03 had not expired. The vaccinee did not experince any adverse reaction following administration. Follow up pending.
This case is 1 of a cluster of eight patients who experienced similar events following vaccination with FLUZONE. A 7-year-old male child received on 23 September 2010 an injection (site and route not reported) of FLUZONE, lot number UH201A. The patient developed within 5 hours or the next day vaccination site pruritus, vaccination site inflammation, and cellulitis. The patient had no illness at the time of vaccination and his medical history was not reported. The outcome was reported as recovered. The reporter for this case is the same reporter as 2010-06283, 2010-06285 and 2010-05509. Documents held by sender: None.
on 5/30 Patient was found unresponsive at home by spouse and daughter. Transported by EMS to local Emergency Department. Preliminary diagnosis was stroke and tPA was initiated. Patient than transferred to ICU for monitoring. Physical exam performed in ICU. Neurologically Patient was awake, confused, and agitated but no evidence of peripheral deficits was found. CT imaging showed no hemorrhage, extensive small vessel changes, and possible ischemia. MRI showed no acute intracranial findings. Patient continued to improve during stay and was discharged on 6/4. Syncope ALTEPLASE 100 MG ONCE ,LEVETIRACETAM 500 MG Unknown
covid due to reaction from covid vaccine; covid due to reaction from covid vaccine/she took second dose of vaccine and has been sick ever since; This is a spontaneous report from a contactable consumer, the patient, based upon information received by Pfizer from Bristol-Myers Squibb (BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-020962), license party for apixaban (ELIQUIS).  This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (COVID due to reaction from COVID vaccine/she took second dose of vaccine and has been sick ever since) in 79-year-old female patient who received apixaban (Eliquis) for an unknown indication.   CO-SUSPECT PRODUCTS included Covid-19 Vaccine (unspecified manufacturer) for COVID-19 immunisation.    On an unknown date, the patient started Eliquis (Oral), 5 milligram twice a day and 2 doses of Covid-19 Vaccine (unspecified manufacturer) (unknown route). On 01-Mar-2021, the patient experienced COVID-19 (COVID due to reaction from COVID vaccine/she took second dose of vaccine and has been sick ever since). The action taken with Eliquis(Oral) was unknown. At the time of the report, COVID-19 outcome was unknown.      For Eliquis (Oral), the reporter did not provide any causality assessments.  No follow-up attempts are possible, information on batch number cannot be obtained.
Instead of the injection being injected into the delta muscle, he received it in teh bursa area of his shoulder; A spontaneous report was received from a consumer concerning a male patient who received an Moderna vaccine injection into the wrong body part (bursa).  The patients medical history was not provided. Concomitant product use was not provided/unknown by the reporter.  The patient received their first of two planned doses of mRNA-1273 (Batch number not provided) on 01-FEB-2021 in the bursa area of his shoulder for prophylaxis of COVID-19 infection.  Instead of the injection being injected into the delta muscle, the patient received it in the bursa area of his shoulder.   Treatment information was not provided/unknown.  Action taken with mRNA-1273 in response to the event was not provided/unknown.  The event was considered recovered/resolved.; Reporter's Comments: This report refers to a case of incorrect route of product administration for mRNA-1273 (lot # unknown) with no associated AEs reported.
Suspected vaccination failure; got shingles; blister; bumps itch; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced vaccination failure (Verbatim: Suspected vaccination failure) (serious criteria GSK medically significant), shingles (Verbatim: got shingles), blister (Verbatim: blister) and itchy rash (Verbatim: bumps itch).  The outcome of the vaccination failure was unknown and the outcome of the shingles, blister and itchy rash were not reported.   It was unknown if the reporter considered the vaccination failure, shingles, blister and itchy rash to be related to Shingles vaccine.   It was unknown if the company considered the vaccination failure, shingles, blister and itchy rash to be related to Shingles vaccine.   Additional Information: GSK Receipt Date: 17-SEP-2023 This case was reported by a patient via interactive digital media. The patient had shot and got shingles with no pain but blister bumps and itch. The reporter asked if anybody had this reaction. This case was considered as suspected vaccination failure since the details regarding completion of primary immunization schedule, time to onset and laboratory test confirming shingles were unknown at the time of reporting.  Follow-up was not possible as no contact details were available.
Droopy right eye- Bell?s palsy.  Eye tearing. Treatment- Retain- mgd
3 days post vaccination, had skin rash on left side of face, shooting pain that went into teeth. Had to keep water in mouth to help pain. Went to urgent care on 7/3/18. Dx'd as herpes zoster without complications on left side of face. Prescribed VALTREX. Has not yet resolved. Went to ER on 7/4/18 because pain did not subside. ER Dx'd as Zoster with facial pain, was told to continue VALTREX and was given pain medication as well. Still not resolved today 7/5/18.
Dr had called health dept to report that pt had low grade fever (100.9); feeling of malaise, faint rash, urticaria, photosensitivity.
Redness of the area around the vaccine injection; Itching of the area around the vaccine injection; Swelling of the area around the vaccine injection; Heat of the area around the vaccine injection; Hurts; Hard knot at injection site; Hard knot at injection site; This case was reported by a consumer via call center representative and described the occurrence of injection site erythema in a elderly female patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included shingles (twice).   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, 1 day after receiving Shingrix, the patient experienced injection site erythema, injection site itching, injection site swelling, injection site warmth, injection site pain, injection site induration and injection site mass. The patient was treated with benadryl (nos) (Benadryl), naproxen (Aleve) and ibuprofen (Advil). On an unknown date, the outcome of the injection site erythema, injection site itching, injection site swelling, injection site warmth, injection site pain, injection site induration and injection site mass were not recovered/not resolved.   It was unknown if the reporter considered the injection site erythema, injection site itching, injection site swelling, injection site warmth, injection site pain, injection site induration and injection site mass to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient received Shingrix and the area was fine the day after receiving the vaccine. The patient experienced redness, hard knot, and heat appeared the 2nd day after the shot and was really miserable that day. The patient rested the 3rd day and continued taking Benadryl and Aleve. The reporter was asking if rest would help to reduce the redness, itching, swelling, hard knot and heat of area around the injection site. That area was bright red and both hurts and itched much like when she had shingles.
Pt recv vax on 12/8/98; 1/2 hr post vax pt exp muscle soreness, shoulder pain/red, flushing on left thigh, warm ear
After receiving the vaccine I had some common side effects such as nausea, vomiting, fever, chills, achiness, and headache, but after several hours I tried to get out of bed and I lost consciousness. In addition I had two episodes of intense sweating and dizziness.
Greater than 35 days between Moderna Covid-19 vaccinations.; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Greater than 35 days between Moderna Covid-19 vaccinations.) in a 37-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (Greater than 35 days between Moderna Covid-19 vaccinations.). At the time of the report, PRODUCT DOSE OMISSION ISSUE (Greater than 35 days between Moderna Covid-19 vaccinations.) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication were provided.  No treatment  medication were provided
Pt returned on 1/12/00, c/o swelling & heat in L/deltoid. Arm very red, measuring 15cm x 15cm. Pt was referred to ER. The Dr there gave her Keflex, Prednisone & instructed her to apply warm, moist packs to her arm 4 x's daily.
Painful reaction; fever; This case was reported by a nurse via sales rep and described the occurrence of pain in a 64-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, 2 days after receiving Shingrix, the patient experienced pain and fever. On an unknown date, the outcome of the pain and fever were unknown.   It was unknown if the reporter considered the pain and fever to be related to Shingrix.  Additional details were provided as follows: The patient received Shingrix and had painful reaction no redness and swelling and reported fever. The patient felt this way for two days after shot. The shot was received at family pharmacy. The provider could not confirm whether or not from shot. The reporter agreed to follow up from GlaxoSmithKline
Site: Pain at Injection Site-Mild, Systemic: Nausea-Medium, Systemic: Vomiting-Medium, Systemic: Other- Light-headed, numbness ONLY in lower hand and wrist-Medium
This spontaneous report was received from a consumer refers to an unspecified number of patients of 50 year old and unknown gender enrolled in a market research. Medical history and concurrent conditions were not reported. On an unknown date the patients were vaccinated with GARDASIL (route, dosage, lot# and expiration date were not reported). Concomitant therapy was not reported. The consumer informed that on an unknown date a physician was discussing patients he vaccinated with GARDASIL and said that he vaccinated 50 years old people, which was potentially off label usage. This is one of several reports received from the same reporter. Additional information has been requested.
Chills, fever (110 deg), body aches, fatigue, headache lasting 24 hours.
Case retrieved from the literature on 04 September 2013. A 53-year-old male patient presented with a complaint of "seeing a purple haze in his right eye (00) for 3 days." Ocular history was significant for remote ptetygium excision OD. Medical history, in addition to hepatitis B and C, was significant for polysubstance abuse, for which he had recently entered rehabilitation. He was currently taking buprenorphine and naloxone. He had received an influenza vaccine (manufacturer unknown, batch number, route and site of administration not reported) 10 days before noting visual symptoms. Initial examination revealed corrected visual acuity of 20/25 -2 OD and 20/20 OS. Results of pupillary reactions, confrontational visual field, color vision, and intraocular pressure were all within normal limits. An unremarkable anterior segment examination and quiet vitreous were noted. Fundus examination in right eye revealed multiple white lesions at the level of outer retina/RPE with a granular foveal appearance. Fluorescein angiography (FA) revealed early multiple punctate hyperfluorescent spots with late taining, which also involved the optic nerve head. Initial Humphrey 30-2 visual field was of low reliability, but follow-up testing revealed residual enlargement of the blind spot with a paracentral scotoma, which improved over. A diagnosis of MEWDS was made and the patient was followed with serial examinations. At the 1-month visit, the patient noted improvement in symptoms. Fundus lesions resolved and vision recovered to 20/20.
Mother reports fever of 102 after administration of vaccines, lasting until morning of 11/6/2015. Fever would resolve with administration of Tylenol and Motrin but then would return. Scheduled pediatrician appointment for afternoon of 11/6/15; coincided with well-child checkup.
On 2/23/2021, 1 week after my first shot of the vaccination (on 2/16/2021), I experienced an slightly itchy arm right around the injection sight. Later in the day I noticed that same area turn red. The following day the reddened, itchy, area became slightly darker in color but less red and had a darker ring around the edge of the discolored area. The next day the discolored area looked the same. By Friday (2/26/2021) the discolored area began to go away but the ring around it was still prominent.
Vaccination site pain; Triedness; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Vaccination site pain) and FATIGUE (Triedness) in an 85-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     Concurrent medical conditions included Lung cancer. Concomitant products included OSIMERTINIB MESILATE (TAGRISSO) for an unknown indication.    In April 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE PAIN (Vaccination site pain) and FATIGUE (Triedness). At the time of the report, VACCINATION SITE PAIN (Vaccination site pain) and FATIGUE (Triedness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment medication includes - Ointment   This case was linked to MOD-2021-253210 (Patient Link).
Per mom arrived home called clinic @ 3:00PM stated baby stopped breathing EMS called. Per mom recovered.
Bursitis; Bumped Elbow; This spontaneous case was reported by a consumer and describes the occurrence of BURSITIS (Bursitis) and JOINT INJURY (Bumped Elbow) in an 87-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 15-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 29-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced BURSITIS (Bursitis) and JOINT INJURY (Bumped Elbow). The patient was treated with PREDNISONE for Bursitis, at a dose of 1 dosage form. At the time of the report, BURSITIS (Bursitis) and JOINT INJURY (Bumped Elbow) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication were reported by reporter.   This case was linked to MOD-2021-231156 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 16-Jul-2021: Follow-up information received on contains non-significant information - added reporter's Email Address.
I woke up throwing up all day headache body pain ticks and tremors this was yesterday i was hot and cold cold and hot i still have little ticks and tremors here and there
Prescription to administer Shingrix to 44 year-old; This case was reported by a pharmacist via call center representative and described the occurrence of intercepted drug prescribing error in a 44-year-old patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient did not receive Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced intercepted drug prescribing error. On an unknown date, the outcome of the intercepted drug prescribing error was unknown.   Additional Information: GSK Receipt Date: 28-OCT-2022 Reporter's Comment: The reporter was a pharmacist. The reporter reported that she received a prescription to administer Shingrix vaccine to the patient that was 44 years old. The reporter stated that the patient was not immunosuppressed or immunocompromised. The reporter would clarify with the prescriber. The reporter stated that the vaccination had not been administered at the time of reporting. Additional supportive information: The reporter received the prescription to administer the Shingrix vaccine to the 44 years old patient which was less than the approved age and the patient did not received the vaccine, which led to intercepted drug prescribing error. Follow-up would not possible, as no contact details were available.